D-0148-2021 Class II Terminated

Recalled by Biogen MA Inc. — Research Triangle Park, NC

FDA drug recall D-0148-2021 was initiated by Biogen MA Inc. on Dec 9, 2020 and is designated Class II. Reason for recall: Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing. The recall status is terminated (terminated Sep 17, 2021). Affected quantity: 5,307 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 23, 2020
Initiation Date
Dec 9, 2020
Termination Date
Sep 17, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,307 bottles

Product description

Vumerity (diroximel fumarate) delayed-release capsule, 231 mg, packaged in a) 106-count bottle, b)120-count bottle, Rx only, Manufactured for: Biogen Inc., Cambridge, MA 02142, NDC 64406-020-01

Reason for recall

Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing.

Distribution pattern

USA Nationwide

Code information

Lot #: a) 101801, Exp 5/31/2021; 102826, Exp 6/21/2021; b) 101799, Exp 5/31/2021; 102362, Exp 6/21/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0148-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0148-2021. Report a data issue: hello@regdatalab.com.